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Abstract
Background: In Japan, gargling is a generally accepted way of preventing upper respiratory tract
infection (URTI). The effectiveness of gargling for preventing URTI has been shown in a randomized
controlled trial that compared incidences of URTI between gargling and control groups. From the
perspective of the third-party payer, gargling is dominant due to the fact that the costs of gargling
are borne by the participant. However, the cost-effectiveness of gargling from a societal
perspective should be considered. In this study, economic evaluation alongside a randomized
controlled trial was performed to evaluate the cost-effectiveness of gargling for preventing URTI
from a societal perspective.
Methods: Among participants in the gargling trial, 122 water-gargling and 130 control subjects
were involved in the economic analysis. Sixty-day cumulative follow-up costs and effectiveness
measured by quality-adjusted life days (QALD) were compared between groups on an intention-
to-treat basis. Incremental cost-effectiveness ratio (ICER) was converted to dollars per quality-
adjusted life years (QALY). The 95% confidence interval (95%CI) and probability of gargling being
cost-effective were estimated by bootstrapping.
Results: After 60 days, QALD was increased by 0.43 and costs were $37.1 higher in the gargling
group than in the control group. ICER of the gargling group was $31,800/QALY (95%CI, $1,900–
$248,100). Although this resembles many acceptable forms of medical intervention, including URTI
preventive measures such as influenza vaccination, the broad confidence interval indicates
uncertainty surrounding our results. In addition, one-way sensitivity analysis also indicated that
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careful evaluation is required for the cost of gargling and the utility of moderate URTI. The major
limitation of this study was that this trial was conducted in winter, at a time when URTI is prevalent.
Care must be taken when applying the results to a season when URTI is not prevalent, since the
ICER will increase due to decreases in incidence.
Conclusion: This study suggests gargling as a cost-effective preventive strategy for URTI that is
acceptable from perspectives of both the third-party payer and society.
Background
Prevention of upper respiratory tract infection (URTI) rep-
resents a major public health issue. An average of 2.5 URTI
episodes are reportedly experienced annually in the
United States[1,2]. In Japan, 4.02% of physician visits are
due to URTI, and the number of patients who consult
physicians due to URTI has been estimated as 223 of
100,000 in a day[3]. Uniquely in Japan, gargling is gener-
ally accepted and strongly recommended as a preventive
measure for URTI. In addition to hand washing and the
wearing of masks, the current guidelines for dealing with
pandemic influenza in Japan also recommend gargling as
a preventive measure[4].
Although the evidence for URTI prevention by gargling is
limited, the effectiveness of gargling for preventing URTI
among healthy people was shown in a randomized con-
trolled trial that compared incidences of URTI between
gargling and control groups[5]. This trial noted a 36%
decrease in the incidence of URTI with water gargling.
In Japan, annual health care expenditures associated with
acute URTI, including hospital fees and prescription med-
icines, total around US$5 billion[5]. A reduction in URTI
incidence by up to 36% with water gargling would equate
to a saving of approximately US$2 billion in annual
health care costs[5]. From the perspective of patients, gar-
gling is somewhat time-consuming, but can prevent about
one-third of URTI cases. The decision on whether to gargle
is up to the individual. From the perspective of the third-
party payer, gargling is a dominant preventive strategy due
to the fact that the opportunity cost of gargling is imposed
on the participant. However, the cost-effectiveness of gar-
gling from a societal perspective should be fully consid-
ered. A trade-off exists between effectiveness for reducing
the incidence of URTI and the opportunity costs incurred.
An economic evaluation was therefore performed along-
side a randomized controlled trial to evaluate the cost-
effectiveness of gargling for preventing URTI from a soci-
etal perspective.
Methods
Setting and patients
From December 2002 through January 2003, healthy
adult volunteers aged between 18 and 65 years were
recruited and randomly assigned to a water gargling
group, povidone-iodine gargling group or control group,
as described in detail previously[5]. A total of 387 subjects
Table 1: Characteristics and outcomes of the RCT subjects
Gargling (n = 122) Control (n = 130)
Baseline characteristics
Gender (male/female) 39/83 43/87
Age (mean) 34.7 36.2
Anti-influenza vaccination (%) 14.3 19.2
Frequency of URTIs in preceding year 14/71/36 16/78/36
(0/1–2/> = 3 times)*
Outcomes of the trial
Infected cases (%)** 30.1 40.8
Incidence rate per 60 person-days 0.34 0.52
Duration of illness (days) *** 88 156
* Data missing for 1 participant.
** Estimated by Kaplan-Meier.
*** Duration of moderate or severe URTIBMC Health Services Research 2008, 8:258 http://www.biomedcentral.com/1472-6963/8/258
Page 3 of 7
(page number not for citation purposes)
participated in the study. Excluded from analysis were 2
subjects who displayed URTI on the first day of interven-
tion, and 1 subject who did not write in the diary at all
(follow-up, 99%). Included in the analysis were a total of
384 patients, with 122 patients in the water-gargling
group, 132 patients in the povidone/iodine-gargling
group, and 130 patients in the control group. Baseline
characteristics and outcomes of gargling and control
groups are shown in Table 1.
Gargling groups were instructed to gargle with approxi-
mately 20 ml of water or povidone-iodine for about 15 s,
3 times/day. Control groups were instructed to retain pre-
vious gargling habits. The primary outcome measure was
first URTI incidence within 60 days. Sample size of the
trial was calculated at a power level of 0.90 and a signifi-
cance level of 0.05. Analyses were performed on an inten-
tion-to-treat basis.
Frequency of gargling and presence of various URTI com-
plaints in all subjects were also assessed using the self-
administered record (gargling diary). All URTI com-
plaints, such as nasal symptoms, pharyngeal symptoms,
bronchial symptoms, pharyngeal symptoms, bronchial
symptoms and general symptoms were recorded and clas-
sified by each subject into 4 grades as none, mild, moder-
ate or severe, according to Jackson methods[6]. "Mild"
was defined as being unaware of the symptom when busy,
"moderate" as always feeling discomfort, and "severe" as
having difficulties in completing the usual activities of
daily living. Subjects who developed URTI were asked to
continue completing the gargling diary for 1 week after
onset of URTI symptoms to confirm the incidence and
severity of URTI.
No subjects assigned to the water-gargling group skipped
gargling, while 36 subjects (28%) in the control group did
not gargle at all. Compared to 50 subjects (40.8% by Kap-
lan-Meier estimation) in the control group, 34 subjects
(30.1%) in the water-gargling group (p = 0.044) and 46
subjects (37.2%) in the povidone/iodine-gargling group
(p = 0.59) had developed URTI as of day 60. Incidences
were lower in water-gargling subjects (0.34 episodes/60
person-days) and povidone/iodine-gargling subjects
(0.48 episodes/60 person-days) than in controls (0.52
episodes/60 person-days), and rate ratios compared to
controls were 0.64 (95% confidence interval (95%CI),
0.42–0.99) and 0.89 (95%CI, 0.60–1.33), respectively. In
the present study, the cost and effectiveness of water gar-
gling were determined by comparison with the control
group. All study protocols were approved by the ethics
committee of Kyoto University.
Costs of care
The 60-day cumulative follow-up costs for all trial partici-
pants were estimated from a societal perspective. All costs
were converted into US dollars according to Purchasing
Power Parities in 2005[7], with a dollar considered equiv-
alent to about 128 Japanese yen.
Costs of gargling, physician consultations due to URTI,
medications to treat URTI, and lost productivity due to
severe URTI were estimated (Table 1). Costs of gargling
were estimated as the opportunity costs of the time
required for gargling by multiplying the time to complete
a single session of gargling, the frequency of gargling in
each group, and the mean wage of Japanese workers[8].
Time to complete a single session of gargling, including
going to and returning from the washroom, was deter-
mined based on 12 individuals who were not participants
in this trial, with gargling considered to require an average
of 71 s.
The cost of a physician consultation was estimated by
multiplying the proportion of subjects who visited physi-
cians due to URTI and the costs involved in such visits.
The proportion of subjects who visited physicians was
obtained from the literature[9], since this information
was not recorded in the gargling trial. The cost of physi-
cian consultation was estimated from the sum of the first
visit fee, the cost of the time required for the consultation,
and the transportation fee. The latter two costs were
obtained from the Patients' Behavior Survey[10], with
time converted to a cost based on national wage and labor
time statistics[11]. The daily cost of medicine was esti-
mated based on the Survey for Individual Medical Proce-
dures[11]. The cost of lost productivity was estimated
assuming that patients with severe URTI were unable to
work all day. All costs are expressed in 2005 costs.
Effectiveness
Effectiveness was measured in quality-adjusted life days
(QALD). Utility was assigned to each day according to the
duration and severity of URTI, with the 60-day cumulative
QALD gained calculated for each strategy. Utilities in
severe and moderate URTI were considered to be
decreased. These utilities were derived from a previous
study that measured utility in influenza[12]. Health states
in severe URTI were estimated as the average utility from
day 1 to day 3 of influenza, and in moderate URTI as the
average utility from day 4 to day 7 of influenza (Table 1).
Analysis
Differences in 60-day cumulative follow-up costs and
effectiveness between gargling and control groups were
compared on an intention-to-treat basis, and the incre-
mental cost-effectiveness ratio (ICER) was derived.
In this trial, the endpoint was the onset of URTI, and
affected patients were censored. The average cost and
effectiveness for each day were therefore estimated based
on those from the number of participants observed onBMC Health Services Research 2008, 8:258 http://www.biomedcentral.com/1472-6963/8/258
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each day, then the 60-day average cost and effectiveness
were summed to calculate differences between groups.
Censoring in the cost estimation was adjusted according
to the methods described by Lin et al[13]. ICER was calcu-
lated from differences between gargling and control
groups in 60-day cumulative costs and QALD. The ICER
unit was converted to quality-adjusted life years (QALY)
for convenience. The 95%CIs were calculated using the
bootstrap method, using 5000 resamplings with replace-
ment of participants in this trial.
Sensitivity analysis
One-way sensitivity analyses were performed for all costs
and utilities within ± 50% ranges to assess the effects of
uncertainty related to parameter estimates. Further two-
way sensitivity analyses were applied to evaluate combi-
nations of gargling cost and utility of moderate URTI.
Results
Of the 384 participants in the gargling trial, 122 subjects
assigned to water-gargling and 130 subjects assigned to
the control group were included in the economic analysis.
Baseline characteristics of the two groups are shown in
Table 2. During the 60-day follow-up, incidence of the
first URTI was 0.26 episodes/30 person-days in the con-
trol group and 0.17 episodes/30 person-days in the water-
gargling group[5].
Estimated costs and effectiveness after 60 days (Table 3)
The 60-day cumulative follow-up costs were estimated at
$105.3 for the gargling group and $68.2 for the control
group, respectively. Difference between the groups was
$37.1 (95%CI, $7.40–$65.40). The costs of gargling for
each group were $80.40 in the gargling group and $17.80
in the control group, representing a $62.6 increase in the
gargling group. The costs of URTI were $24.9 in the gar-
gling group and $50.4 in the control group. Cost was thus
$25.50 lower in the gargling group. The 60-day QALD was
59.52 in the gargling group and 59.10 in the control
group, showing that QALD was greater by 0.43 (95%CI,
0.07–0.80) in the gargling group (Table 3).
Cost-effectiveness analysis (Table 3)
The incremental cost per QALY gained associated with
gargling was $31,800 (95%CI, $1,900–$248,100). Boot-
strapped estimates of the incremental costs and incremen-
tal QALD are shown in Figure 1 using the cost-
effectiveness plane. Figure 2 shows that, given a willing-
ness-to-pay threshold of $50,000/QALY, the probability
of gargling being cost-effective compared with control is
69.8%. If the threshold is increased to $100,000, then the
probability increases to 89.9%.
Sensitivity analyses (Table 4)
One-way sensitivity analysis showed that the ICER of gar-
gling is highly sensitive to the cost of gargling and the util-
ity of moderate influenza (Table 4). These 2 critical factors
were studied further using two-way sensitivity analysis.
Figure 3 shows the combination of gargling cost and util-
ity of moderate URTI.
Table 3: Results of cost effectiveness analysis
Cost($) Incremental
cost (95%CI)**
Effectiveness
(QALD)
Incremental
effectiveness (95%CI)
ICER($/QALY)
(95%CI)**
Gargling
Cost of gargling 80.4 62.6
Cost of URTI 24.9 -25.5
Total 105.3 37.1 
(7.4–65.4)
59.52 0.43 
(0.07–0.80)
31,800 
(1,877–248,095)
Control
Cost of gargling 17.8
Cost of URTI 50.4
Total 68.2 59.10
QALD = quality adjusted life days.
ICER = incremental cost-effectiveness ratio.
**95% confidence intervals calculated by the bootstrap method.
Table 2: Estimated costs and utility
Variable Value
Cost per day
Gargling (once) $0.4
Visiting physicians (once)* $47.9
Medicine (per day) $2.0
Lost productivity due to severe URI (per day) $97.7
Utility
Moderate URI 0.63
Severe URI 0.24
* Only 36% of those who developed URI were assumed to visit a 
physician.BMC Health Services Research 2008, 8:258 http://www.biomedcentral.com/1472-6963/8/258
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ICER for gargling varied from $5,000 to $58,600 when the
cost of gargling ranged from $0.2 to $0.6. In addition,
ICER varied from $21,000 to $64,800 when the utility of
moderate influenza ranged from 0.32 to 0.95. ICER of gar-
gling did not exceed $50,000/QALY in sensitivity analyses
involving the following variables: cost of physician con-
sultations due to URTI; cost of medications to treat URTI;
and utility of severe influenza.
Discussion
Although several limitations are inherent to performing
an economic analysis alongside a randomized trial[14],
this approach allowed quantification of the cost-effective-
ness of gargling. Gargling generated a 0.43 increase in
QALD and $37.1 higher costs compared with the control
group. Although gargling generated a higher QALD by
preventing URTI, the daily cost of gargling exceeded the
cost of the URTI saved by gargling. ICER of the gargling
group was $31,800/QALY (95%CI, $1,900–$248,100).
This is similar to many acceptable forms of medical inter-
vention, including URTI preventive methods such as
influenza vaccination[12,15,16]. Although ICER of gar-
gling was within the range of acceptable forms of URTI
preventive methods such as influenza vaccina-
tion[12,15,16], the broad confidence interval indicates
uncertainty surrounding our results. In addition, one-way
sensitivity analysis showed that the cost of gargling and
the utility of moderate URTI exerted a large impact on the
cost-effectiveness of gargling. Careful evaluation is thus
required for those variables.
We estimated the cost of gargling based on the average
wage of Japanese workers based on the assumption that
patients lost productivity due to gargling. If the impact on
productivity is minimized and the cost of gargling can be
maintained at lower than $0.16 (lower than the lower
limit of the cost used in sensitivity analysis) gargling will
be dominant.
The cost effectiveness of gargling also depends on how
effectively it can reduce the incidence of influenza-like ill-
nesses (ILI). The gargling trial was designed to evaluate the
effectiveness of gargling for preventing URTI among
healthy individuals, and therefore excluded ILI. Further
analysis focusing on ILI was subsequently performed
using the same data set[17]. Although no statistical signif-
icance was achieved due to the small number of ILI, anal-
ysis indicated a tendency toward decreased incidence of
ILI with water gargling (hazard ratio, 0.75; 95%CI, 0.32–
1.72). If the effectiveness of gargling in preventing ILI
were to be demonstrated in a further study involving a
large sample, the cost-effectiveness of gargling would be
improved due to decreases in the number of patients suf-
fering from complications of ILI and decreased use of
oseltamivir.
Scatter plot of simulated mean cost and effect differences in  60 days Figure 1
Scatter plot of simulated mean cost and effect differ-
ences in 60 days. Five thousand bootstrap samplings were 
used for the incremental cost and effectiveness of the gar-
gling group compared to the control group. The plot indi-
cates that 0.9% of all cases are located in area 1 indicating 
that  gargling is dominant, 98.2% of total cases are located in 
area 2 indicating that gargling is more costly and effective 
than control, and 0.9% of all cases are located in area 3 indi-
cating that gargling is dominated by control.
Area 2
Area 1
Area 3
Acceptability curve Figure 2
Acceptability curve. The curve indicates the probability of 
gargling being preferable to the control for potential maxi-
mum amounts that a decision-maker is willing to pay for an 
additional increase in QALY. WTP, willingness to pay.
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The major limitation of our study was that this trial was
conducted in winter, the season of maximum URTI prev-
alence. Care must therefore be taken when applying our
results to seasons in which URTI is less prevalent, since the
ICER will increase with a lower URTI incidence. Second,
estimated costs for URTI, particularly for physician con-
sultations resulting from URTI, were based on the
assumption that the proportion of patients who visit clin-
ics is 36%[9]. We examined the impact of variability of
costs for URTI with one-way sensitivity analysis and
showed the variability did not significantly affect the
result. Finally, we were unable to estimate all opportunity
costs, such as time required for dedicated trips to the
washroom to gargle, as no precise data were available.
Conclusion
In conclusion, the present study suggests that gargling has
potential as a cost-effective preventive strategy for URTI
that is acceptable from both third-party payer and societal
perspectives. However, careful consideration of the uncer-
tainties surrounding the estimation of ICER for gargling is
required.
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